Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,082 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Type 1 (HIV-1) Clear all
Active, not recruiting Phase 4 Interventional

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

NCT05220358
View directory record Official record
Conditions
HIV-1-infection
Interventions
Fostemsavir 600 MG [Rukobia]
Drug
Lead sponsor
Orlando Immunology Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

NCT00000775
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

NCT00089492
View directory record Official record
Conditions
HIV Infections
Interventions
Optimized Background ARVs, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Hobson City, Alabama • Fountain Valley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 3:14 PM EDT
Completed No phase listed Observational

A Comparison of Two Tests for Anti-HIV Drug Resistance

NCT00006490
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

NCT00529243
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Anaheim, California • Hayward, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Not applicable Interventional

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

NCT00001075
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 3:14 PM EDT
Completed No phase listed Observational

The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis

NCT00341172
View directory record Official record
Conditions
AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years to 100 Years
Enrollment
2,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 14, 2026, 3:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

NCT00001681
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

NCT00002193
View directory record Official record
Conditions
HIV Infections
Interventions
Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
6 Months to 18 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View directory record Official record
Conditions
HIV-1-infection
Interventions
PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
Biological · Device
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

NCT02039323
View directory record Official record
Conditions
Healthy Adult Females
Interventions
Tenofovir, Maraviroc
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 14, 2026, 3:14 PM EDT
Terminated No phase listed Observational

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

NCT01474954
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Not applicable Interventional

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002401
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01108510
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Results available

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

NCT00071760
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GW433908, ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

NCT03399903
View directory record Official record
Conditions
HIV-1-infection, Gut Inflammation
Interventions
Pentasa vs Align
Drug
Lead sponsor
AIDS Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Not applicable Interventional Results available

R5 Integrase Study in HIV-1 Naive Patients

NCT01204905
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Maraviroc in combination
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 14, 2026, 3:14 PM EDT
Terminated Early Phase 1 Interventional

Gene Transfer for HIV Using Autologous T Cells

NCT01153646
View directory record Official record
Conditions
HIV-1 Infection
Interventions
pHIV7-shI-TAR-CCR5RZ treated CD4 cells
Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 4 Interventional Results available

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

NCT01777997
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

NCT02422797
View directory record Official record
Conditions
HIV Infections
Interventions
DTG 50 mg, RPV 25 mg, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

NCT00920426
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 30mg, Placebo, GSK1265744 5mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Vero Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

NCT00038480
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Days to 6 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
14
States / cities
Oakland, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children

NCT00000843
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 3:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT05729568
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 14, 2026, 3:14 PM EDT